Bliss GVS Pharma Ltd share Price

Bliss GVS Pharma Limited is a company that operates in the manufacturing of pharmaceutical products and has a market capitalization of Rs 1,038.74 Crores on 24th August '2021. In 1984, it became a corporation as a private limited company by the name “Bliss Chemicals & Pharmaceuticals India Limited”, and the company commenced its business in the year 1985. At the end of March 2020, it registered combined revenue of Rs 689.31 Crores. The Bombay Stock Exchange (BSE) and National Stock Exchange have assigned the number 506197 and scrip code BLISSGVS. As of 24th August '2021, Bliss GVS Pharma Limited is trading at Rs. 100.50.

The company has four wholly owned subsidiaries and three step-down subsidiaries as of 31st March 2020. BGPL is developing on its global expertise and gaining a leadership position in anti-malarial, anti-fungal, dermatological, anti-inflammatory branded formulations. The plant is well equipped to manufacture various dosage forms like Tablets, Capsules, Dry Syrups, and Sachets, etc., with a capacity of ~420 MN per annum. Bliss GVS Pharma Limited has a strong geographical foothold presence in more than 60 countries from Africa to North America to Southeast Asia with more than 250 brand formulations. In FY20, the geographical revenue mix from sub-Saharan Africa was 76%, followed by India contributing 21% and the Rest of the World at 3%. It has 663 permanent employees on the rolls as of 31st March 2020. The promoters and promoter’s group holds 41.60% of the stake within the company, and the rest, 58.40%, is owned by the others (public shareholding).

In June 2021, total sales were Rs 140.93 Crores, up 16.50% from Rs 120.97 Crores in June 2020. The quarterly Net Profit in June 2021 was Rs. 21.66 Crores, up 26.67% from Rs. 17.10 Crores in June 2020. In June 2021, operating profit was Rs. 117.55 Crores, up 8.04% from Rs. 108.81 Crores in June 2020. From Rs. 1.66 in June 2020, Bliss GVS Pharma Limited’s EPS has risen to Rs. 2.10 in June 2021. From 13% in March 2019, Bliss GVS Pharma Limited’s return on capital employed has increased to 14.36% in March 2020.